Katsuki Arima

My Team!

Highlights on #ESMOBreast26 from #CommunityOnc: Her2 1. #DB11 Update: NeoAdj TDXd 2. #PHERGain: De-escalation 3. #SATEEN: Sacituzumab HR+ 4. #PREcoopERA: Role of OFS 5. #CAPItello291 Update: Capivasertib TNBC 6. #TROPIONBreast02: DatoDXd #OncTwitter #bcsm @myESMO 1/7

Interesting data showing that upfront SLNB may be reasonable for select patients presenting with cN1 HR+/HER2- breast cancer - no recurrences in those with at least 12 months of f/u at time of analysis

What happened this week in #BreastCancer: 1⃣ FDA approval of PROTAC ER degrader in ESR1m Regulatory clearance of vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic disease after endocrine therapy based on VERITAC-2 positions it as a new post CDK4/6i endocrine option with improved PFS vs fulvestrant and necessitates ESR1 testing via the simultaneously approved companion diagnostic to detect ESR1 mutations. fda.gov/drugs/resource…

#ESMOBreast26 Neoadjuvant immunotherapy in ER+/HER2− early BC is still an open question. A pCR signal is interesting, but not enough in this subtype. We need EFS data..... From Dr. Rebecca Dent's excellent presentation. Pragmatic strategy👇

📌 Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine for triple-negative breast cancer (TNBC) with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21) @OncoAlert #OncoAlertAF #ESMOBreast26 ✨Proferred Paper

📌 A window-of-opportunity (WOO) trial of giredestrant +/- LHRH analogue vs anastrozole + LHRHa in premenopausal patients with ER+/HER2- early breast cancer: PREcoopERA @elisabettasabet ✨ #ESMOBreast26 @OncoAlert #OncoAlertAF ✨ Proferred Paper

PREcoopERA Trial: Oral SERD Activity in Premenopausal HR+ Early #BreastCancer, Promise Without Replacement Yet 🧬 Giredestrant with or without ovarian suppression shows robust Ki67 reduction in premenopausal HR+ early breast cancer, ⬇️⬇️ @OncoAlert #ESMOBreast26 #bcsm

DESTINY-Breast11: T-DXd–Based Neoadjuvant Therapy Outperforms Anthracycline-Containing Regimens in High-Risk HER2+ EBC, Delivering Higher pCR and RCB 0/1 Rates and Supporting a Shift Toward an Anthracycline-Free Standard @OncoAlert #ESMOBreast26

Simultaneous publication with #ESMOBreast26 An excellent de-escalation study: PHERGain-2 study A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer sciencedirect.com/science?_ob=Ga…

Esmo Breast 2026 - LBAs are out . What's the new data from Destiny Breast 11 ? It improves RCB across all the subgroups. Looking forward to full data. @myESMO #esmobreast26

My favorite study today at #ESMOBreast: PREcoopERA (IBCSG 67-22), a window-of-opportunity trial in premenopausal ER+/HER2- early BC asking whether giredestrant alone is enough, or whether ovarian suppression is still required. 231 patients → giredestrant alone, G + triptorelin, or anastrozole + triptorelin. Primary endpoint: Ki67 at 4 weeks. Giredestrant alone did NOT meet non-inferiority vs G+OS (-68% vs -80%). And G+OS was not superior to anastrozole+OS (p=0.18). Bottom line: Even for a next-gen SERD, ovarian suppression adds to anti proliferation effect in premenopausal patients. #ESMOBreast #BreastCancer #Giredestrant

Upcoming ADC trials for HR+ mbc. #ESMOBreast26

📌 Chemotherapy-free, pathological complete response (pCR)-guided strategy with trastuzumab-pertuzumab (HP) and T-DM1 in HER2+ early breast cancer (EBC): PHERGain-2 #ESMOBreast26 @OncoAlert #OncoAlertAF

The activating ERBB2 mutations are significantly enriched in invasive lobular carcinoma (ILC) versus NST metastatic breast cancer (10.7% vs 3.0%). Findings highlight the biologic heterogeneity of HER2-mutant HR+ metastatic breast cancer and support more refined biomarker-driven treatment strategies. #bcsm #BreastCancer #PrecisionOncology #esmobreast2026 @Larvol @OncoAlert

HR+/HER2– Early Breast Cancer: From Endocrine Biology to Immune Precision—Redefining Neoadjuvant Strategy @OncoAlert #ESMOBreast26 #bcsm #BreastCancer @myESMO

The Her2 Story. Part 1 Chapter 1; Discovery Chapter 2: Genentech Chapter 3: Clinucak Trial Struggle

A MUST-READ! This is probably one of my most important papers where I try to teach how to fish rather than offer fish. How I Read a Clinical Trial Report? BG’s primer for Busy Clinicians. Thank you @JCOOP_ASCO @EthicsdoctorP for the kind invitation. I hope the readers will find this useful. ascopubs.org/doi/10.1200/OP…

SONIA trial @JAMAOnc : In HR+/HER2− advanced #BreastCancer, first-line CDK4/6i did not improve OS vs delayed use (47.9 vs 48.1 mo; HR 0.91), despite modest PFS gain. Higher toxicity without QoL benefit. jamanetwork.com/journals/jamao… @OncoAlert #bcsm

@nikolas_dm Revoltante!

Enquanto isso aquela criança lá no Maranhão tendo de atravessar o rio nadando pra ir pra escola. Não falta dinheiro nesse país, falta vergonha na cara. Esse ano será o último desse larápio.

📌 18F-Fluorodeoxyglucose Positron Emission Tomography for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer A Nonrandomized Clinical Cohort Trial 🔗 jamanetwork.com/journals/jamao… @OncoAlert #OncoAlertAF #BreastCancer @JAMANetwork @univgroningen 👉🏻 In this clinical cohort trial of patients with nonrapidly progressive, newly diagnosed MBC before initiation of first-line systemic therapy, early FDG-PET after only 2 weeks of treatment identified patients with MBC with distinct long-term outcomes. Incorporating early FDG-PET can improve outcome estimation of standard CT assessment.